Anika Therapeutics (NSDQ:ANIK) has inked an agreement with the Institute of Integrative Biology at the University of Liverpool to develop an injectable mesenchymal stem cell therapy to treat osteoarthritis.
As a result of the three-year research collaboration, the group hopes to have a lead candidate that it can take into clinical trials.
Get the full story at our sister site, Drug Delivery Business News.